Why the Challenge

PV, ET and MF are cancers of the blood. People in a good prognostic group can live for many years without having major symptoms; those with a poor prognosis may progress more quickly.

For a small number of patients, MF can transform to acute myeloid leukemia (AML), a serious blood and bone marrow cancer which progresses quickly. When AML does arise from MF, it is often difficult to treat and can be rapidly fatal.

This is why we need to act now.


The emergence of new treatments for MF patients is encouraging, but until there is proof that these emerging treatments actually change the course of the disease, these fears will remain. MPN Research Foundation jointly with the Leukemia & Lymphoma Society seeks to change this future.

Join us today and change the trajectory for people with PV, ET, and MF.

Partners

LLS Logo MPN Logo